Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

IL-1β a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis.

Kammoun-Krichen M, Bougacha-Elleuch N, Mnif M, Bougacha F, Charffedine I, Rebuffat S, Rebai A, Glasson E, Abid M, Ayadi F, Péraldi-Roux S, Ayadi H.

Eur Cytokine Netw. 2012 Jul-Sep;23(3):101-6. doi: 10.1684/ecn.2012.0312.

2.

Down-regulation of the auto-aggressive processes in patients with hypothyroid Hashimoto's thyroiditis following substitutive treatment with L-thyroxine.

Guclu F, Ozmen B, Kirmaz C, Kafesciler SO, Degirmenci PB, Taneli F, Hekimsoy Z.

Eur Cytokine Netw. 2009 Mar;20(1):27-32. doi: 10.1684/ecn.2009.0147.

4.

Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.

Vitti P, Chiovato L, Fiore E, Mammoli C, Rocchi R, Pinchera A.

Acta Med Austriaca. 1996;23(1-2):52-6.

PMID:
8767515
5.

Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.

Bossowski A, Urban M.

J Pediatr Endocrinol Metab. 2001 Jun;14(6):741-7.

PMID:
11453524
6.

Effects of thyroid status on thyroid autoimmunity expression in euthyroid and hypothyroid patients with Hashimoto's thyroiditis.

Rieu M, Richard A, Rosilio M, Laplanche S, Ropion V, Fombeur JP, Berrod JL.

Clin Endocrinol (Oxf). 1994 Apr;40(4):529-35.

PMID:
8187321
7.

Evaluating the role of Th0 and Th1 clones in autoimmune thyroid disease by use of Hu-SCID chimeras.

Fisfalen ME, Soltani K, Kaplan E, Palmer EM, van Seventer GA, Straus FH, Diaz M, Ober C, DeGroot LJ.

Clin Immunol Immunopathol. 1997 Dec;85(3):253-64.

PMID:
9400625
8.

Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease.

Colao A, Pivonello R, Faggiano A, Filippella M, Ferone D, Di Somma C, Cerbone G, Marzullo P, Fenzi G, Lombardi G.

Clin Endocrinol (Oxf). 2000 Jul;53(1):13-9.

PMID:
10931076
9.

Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.

Mariotti S, Caturegli P, Barbesino G, Marinò M, Del Prete GF, Chiovato L, Tonacchera M, De Carli M, Pinchera A.

Clin Endocrinol (Oxf). 1992 Nov;37(5):415-22.

PMID:
1486691
10.

Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.

Zwirska-Korczala K, Berdowska A, Jochem J, Sitkiewicz A, Birkner E, Polaniak R, Jedrzejowska-Szypułka H, Korzonek-Szlacheta I.

J Clin Pharm Ther. 2004 Apr;29(2):151-6.

PMID:
15068404
12.
13.
14.

Hashimoto's thyroiditis following Graves' disease.

Umar H, Muallima N, Adam JM, Sanusi H.

Acta Med Indones. 2010 Jan;42(1):31-5.

15.

[Thyroid hormone autoantibodies in Hashimoto's disease and Graves' disease].

Nakamura S, Murayama M, Kojima N, Kamikubo K, Sakata S, Yasuda K, Miura K.

Nihon Naibunpi Gakkai Zasshi. 1983 Oct 20;59(10):1597-607. Japanese.

PMID:
6689304
16.

Asymptomatic atrophic thyroiditis.

Bonnyns M, Vanhaelst L, Bastenie PA.

Horm Res. 1982;16(5):338-44.

PMID:
6816712
17.

Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link?

Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE.

Hum Pathol. 2003 Aug;34(8):764-9.

PMID:
14506636
18.

[Risk factors and pathogenesis of Hashimoto's thyroiditis].

Paknys G, Kondrotas AJ, Kevelaitis E.

Medicina (Kaunas). 2009;45(7):574-83. Review. Lithuanian.

19.

Coexistence of papillary carcinoma and Hashimoto's thyroiditis.

Matesa-Anić D, Matesa N, Dabelić N, Kusić Z.

Acta Clin Croat. 2009 Mar;48(1):9-12.

PMID:
19623865

Supplemental Content

Support Center